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Human mononuclear cells were exposed to three antiviral agents, stimulated
with phytohemagglutinin, and assayed for DNA synthesis with [3H]thymidine
uptake and flow cytometric analysis. Cytosine-arabinoside demonstrated inhibi-
tion of blastogenic reactivity by both [3H]thymidine uptake and flow cytometric
analysis, whereas acyclovir showed no significant suppression. In contrast, (E)-5-
(2-bromovinyl)-2'-deoxyuridine, a thymidine analog, demonstrated a lack of
correlation between the two methods. The competitive inhibition of some
compounds with [3H]thymidine incorporation necessitates the use of other
methods to measure DNA synthesis.
Lymphocyte stimulation is commonly utilized
not only as an in vitro method for measuring
cell-mediated immunity in suspected immunode-
ficiency, but also for examining the effects of
potentially toxic drugs on lymphocyte function
(7, 10, 12). Although incorporation of [3H]thymi-
dine to quantitate mitogen- or antigen-induced
lymphocyte stimulation is the most common
assay employed, flow cytometric analysis (FCA)
has recently become popular as a means for
examining similar functions by probing the cell
cycle of lymphocytes. Although reports have
demonstrated a correlation between these test
systems (4, 9), analysis of drug toxicity on
lymphocyte stimulation should be interpreted
with caution when using incorporation of radio-
labeled thymidine because of analog similarities.
Therefore, when investigations are designed to
study the effects of various agents on cell cy-
cling, it must be determined that the added
compound has no effect on the assay system
conditions, particularly the salvage pathway for
thymidine, thymidine metabolism, or intracellu-
lar thymidine pools. The present study was
designed to compare uptake of [3H]thymidine to
FCA with parametric and nonparametric analy-
sis of DNA fluorescence histograms. Three anti-
viral agents were used to demonstrate the poten-
tial discrepancies between these two test sys-
tems.
In vitro cultures were prepared with lympho-
cytes separated from peripheral whole blood by
centrifugation on a Ficoll-Hypaque gradient.
Lymphocyte stimulation responses to phytohe-
magglutinin (PHA) were evaluated alone and
after the addition of the antiviral compounds 1-
P-D-arabinofuranosylcytosine, acyclovir [9-(2-
hydroxyethoxymethyl)guanine], and (E)-5-(2-
bromovinyl)-2'-deoxyuridine (BVdU).
Lymphocytes were incubated for 60 h in a 5%
CO2 humidified atmosphere, after which time
cells were prepared for quantitation of DNA
synthesis by the two methods. In the first meth-
od, [3H]thymidine (4.8 ,ug/ml; specific activity,
20 Ci/mmol) was added 4 h before harvest, and
incorporation of the labeled isotope was quanti-
tated in a liquid scintillation spectrophotometer
as described previously (10). By FCA method-
ology, cultured lymphocytes were washed,
stained with Vindelou propidium iodide, and
then assayed on a Coulter TPS-1 cell sorter (9).
Data were transferred for computer analyses to
parametric and nonparametric histograms as de-
scribed by Bagwell et al. (1).
Previously, we reported the effects of 1-j3-D-
arabinofuranosylcytosine and acyclovir on
PHA-induced lymphocyte transformation by
incorporation of [3H]thymidine (10). 1-1-D-Ara-
binofuranosylcytosine (10 ,ug/ml) significantly
inhibited lymphocyte stimulation (98%), where-
as acyclovir (20 ,ug/ml) had little effect on mito-
gen-induced transformation. Similar findings
were demonstrated by FCA methodology. Sup-
pression of [3H]thymidine incorporation by
BVdU progressively increased when concentra-
tions of >8 ,g/ml were added (Table 1). It
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TABLE 1. Effect of BVdU on PHA stimulated
lymphocyte DNA content by [3H]thymidine
incorporationa
BVdU concn Men±S pb Signflf- %(BVcg/mn) Mea ± SE CPM cancec Inhibition'
0 198,913 ± 19,584
2 183,518 ± 17,382 NS 8
8 168,636 ± 17,842 NS 16
10 146,262 ± 13,697 S 26
20 119,878 ± 13,298 S 40
40 87,864 ± 15,530 S 56
50 67,322 ± 9,715 S 66
60 55,581 + 8,500 S 72
70 51,663 ± 6,827 S 74
80 48,378 ± 7,745 S 76
90 45,791 + 6,834 S 75
100 53,044 ± 8,704 S 73
200 36,792 ± 8,265 S 81
Medium 2,184 ± 530 S
a PHA was used at a concentration of 5 ,g/ml in all
cultures except medium. The final concentration of
thymidine was 4.8 p.g/ml (specific activity, 20 Ci/
mmol).
b Average of 10 assays.
c Significance (S) was defined as P < 0.05; NS, not
significant.
d Calculated by the formula: percent inhibition =
100 - {[cpm of BVdU/cpm of control (no drug)] x
100).
would, therefore, be expected that FCA might
demonstrate a corresponding reduction in the
number of cells in the S and G2 + M phases;
however, this was not the case. By FCA, the
effect of BVdU on PHA-stimulated lymphocyte
DNA content showed no significant inhibition
until high levels were reached (Table 2). A
nonparametric histogram (Fig. 1A) demonstrat-
ed PHA-induced lymphocyte stimulation in the
absence and presence of 4 jxg of BVdU per ml.
Histograms of PHA-stimulated lymphocytes
with BVdU concentrations of up to 60 ,ug/ml
were similar to that shown in Fig. 1. It was not
until 70 ,ug of BVdU per ml was added to the
lymphocyte culture that significant inhibition
was first noted (Fig. 1B). The apparent inhibi-
tion occurs at the early S phase of the cycle with
a compensatory increase in the G2 + M cells as
some lymphocytes complete their response to
PHA stimulation.
BVdU is a thymidine analog and therefore,
the apparent low stimulation observed (Table 1)
may simply be the result of competitive incorpo-
ration of BVdU with the labeled thymidine.
Additional experiments were performed in
which [3H]bromodeoxyuridine (4.8 ,ug/ml; spe-
cific activity, 25.8 Ci/mmol) was substituted for
[3H]thymidine to validate its incorporation into
the DNA of stimulated lymphocytes. It was
demonstrated that the uptake of [3H]bromo-
deoxyuridine was as much as 45% that of
[3Hlthymidine incorporation. This response has
also been demonstrated on mouse L-929 cells
and normal fibroblasts (2, 6). Pelliniemi (8) has
shtown that the thymidine analog deoxyuridine
competitively inhibits the enzyme thymidine ki-
nase and thereby reduces the incorporation of
[3H]thymidine into DNA. Cheng et al. (3), how-
ever, have suggested the possibility of BVdU
acting as an alternate substrate for thymidine
kinase rather than as an inhibitor of thymidine
kinase. Thymidine and deoxyuridine are not part
of the de novo biosynthetic pathway, but are
incorporated into DNA via salvage pathways
(11). These interfering responses have resulted
in misinterpretation of data (5, 7, 12). Therefore,
FCA should be performed to examine the static
representation of cellular DNA content, instead
of measuring the rate of cellular DNA synthesis,
as in the case of [3H]thymidine incorporation.
FCA will also delineate specifically those sup-
pressed stages within the cell cycle itself.
TABLE 2. Effect of BVdU on PHA stimulated lymphocyte DNA content by FCA (Parametric II)a
BVdU concn Mean ± SE % phase distributionb
(Pg/ml) Go + GI S G2 + M Sinfiancec
0 57.8 ± 2.0 30.8 ± 2.1 11.5 ± 0.4
10 51.9 t 2.7 37.8 ± 5.0 10.3 ± 2.4 NS
20 58.9 ± 11.5 31.5 ± 10.8 9.7 ± 0.8 NS
40 65.5 ± 1.9 27.5 ± 3.3 7.1 ± 1.4 NS
50 67.3 ± 4.3 23.2 ± 3.9 9.5 ± 0.9 NS
60 69.4 ± 4.6 21.5 ± 5.2 9.1 ± 1.0 NS
70 67.8 ± 2.1 21.5 ± 2.7 10.6 ± 0.7 S
90 69.7 ± 3.0 20.5 ± 2.2 9.8 ± 0.8 S
100 73.5 ± 2.2 17.5 ± 2.3 9.1 ± 0.1 S
Medium 90.8 t 3.1 8.3 ± 3.2 1.0 ± 0.2 S
a PHA was used at a concentration of 5 p.gml in all cultures except medium.b Mean of three histograms.
S, Significant difference (P < 0.05) between S phase control and BVdU-exposed cultures; NS, not
significant.
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FIG. 1. DNA histograms generated by FCA as PHA-induced human lymphocyte stimulation in the absence
and presence of BVdU. Results are expressed in histogram form, with the ordinate representing number of
particles (cells) and the abscissa analyzing cell counts in each channel, with differences calculated by the Gossett
t test. Each histogram pattern represents the average of four cultures. (A) PHA-stimulated lymphocyte control
(0-0) shows anticipated three phases of cell cycling (Go + G1, S, and G2 + M), as is also demonstrated in the
presence of 4 ,ug of BVdU per ml(....). (B) Comparison of PHA-stimulated lymphocyte control (0-0) with
lymphocytes in the presence of 70 ,ug of BVdU per ml(....).
In the present study, lack of correlation be-
tween the two test systems was clearly the result
of competitive inhibition for [3H]thymidine up-
take by BVdU. For this reason, the necessity of
a reliable method that is independent of the
incorporation of exogenous substances in cul-
ture (such as FCA) would be advantageous
when measuring inhibition of cellular DNA syn-
thesis in drug toxicity studies.
We express our appreciation for the expert technical sup-
port of Deborah Lester and the editorial review provided by
Penni Jacobs and Monarie Carraro.
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